Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) CFO Max Scheder-Bieschin acquired 10,000 shares of the business’s stock in a transaction on Thursday, September 7th. The stock was acquired at an average price of $1.13 per share, with a total value of $11,300.00. Following the transaction, the chief financial officer now directly owns 32,371 shares of the company’s stock, valued at approximately $36,579.23. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Ekso Bionics Holdings, Inc. (EKSO) traded down 2.61% on Friday, reaching $1.12. The company’s stock had a trading volume of 594,918 shares. The firm’s market capitalization is $28.88 million. The firm has a 50-day moving average price of $1.55 and a 200 day moving average price of $2.28. Ekso Bionics Holdings, Inc. has a 52-week low of $0.99 and a 52-week high of $6.38.

TRADEMARK VIOLATION NOTICE: “Insider Buying: Ekso Bionics Holdings, Inc. (EKSO) CFO Acquires 10,000 Shares of Stock” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/09/08/insider-buying-ekso-bionics-holdings-inc-ekso-cfo-acquires-10000-shares-of-stock.html.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Intellectus Partners LLC raised its stake in shares of Ekso Bionics Holdings by 5.3% in the 2nd quarter. Intellectus Partners LLC now owns 105,294 shares of the company’s stock worth $244,000 after buying an additional 5,294 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Ekso Bionics Holdings by 32.9% in the 2nd quarter. Vanguard Group Inc. now owns 711,082 shares of the company’s stock worth $1,650,000 after buying an additional 176,197 shares in the last quarter. National Planning Corp raised its stake in shares of Ekso Bionics Holdings by 116.2% in the 2nd quarter. National Planning Corp now owns 234,450 shares of the company’s stock worth $537,000 after buying an additional 126,000 shares in the last quarter. Carl Domino Inc raised its stake in shares of Ekso Bionics Holdings by 74.7% in the 2nd quarter. Carl Domino Inc now owns 82,054 shares of the company’s stock worth $190,000 after buying an additional 35,088 shares in the last quarter. Finally, Independence Advisors LLC bought a new stake in shares of Ekso Bionics Holdings in the 2nd quarter worth $1,840,000. 6.04% of the stock is currently owned by institutional investors.

Several research analysts have issued reports on EKSO shares. B. Riley reiterated a “buy” rating and issued a $4.00 price objective on shares of Ekso Bionics Holdings in a research report on Monday, May 15th. Zacks Investment Research upgraded Ekso Bionics Holdings from a “hold” rating to a “buy” rating and set a $2.00 price objective for the company in a research report on Wednesday, July 26th.

Ekso Bionics Holdings Company Profile

Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.

Receive News & Ratings for Ekso Bionics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.